-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Upgrades enGene Therapeutics to Overweight, Maintains Price Target to $4

Benzinga·11/12/2026 13:05:04
Piper Sandler analyst Allison Bratzel upgrades enGene Therapeutics (NASDAQ:ENGN) from Neutral to Overweight and maintains the price target from $4 to $4.